Skip navigation

In Search of a Disease-Modifying Agent for Parkinson’s Disease: A Discovery Story

13 November 2017

Parkinson’s disease afflicts an estimated 6.3 million people globally, and there is currently no disease-modifying therapy that halts the progression of the disease. Genentech partnered with Charles River Laboratories to research the possibility of using Leucine-Rich Repeat Kinase 2 (LRRK2) inhibitors as therapeutic agents for the treatment of autosomal-dominant Parkinson’s disease. This report summarizes the exhaustive research process used to identify, optimize and test the safety of a compound that showed promise in inhibiting phosphorylated LRRK2 in the brain.

Full Paper available here:
www2.criver.com/LRRK2